Researchers and doctors at the University of Oxford have begun an evaluation of AI software that could help pathologists diagnose prostate cancer. In the UK, around 46,000 new cases of prostate cancer are reported each year, an increase of 12 per cent over the past 10 years.
Oxford University Hospitals (OUH) is currently testing the technology in a clinical setting, the university has announced. Press release On that day. It is an important milestone in that ARTICULATE PRO review Led by Oxford University.
This two-year project aims to explore AI deployment in the prostate cancer pathway using Paige Prostate. The tool is a computer-aided diagnostic system designed to help pathologists identify, grade and quantify tumors in prostate biopsies or tissue samples. Two NHS trusts – University Hospitals Coventry and Warwickshire and North Bristol NHS Trust – will also evaluate the Paige Prostate Suite software.
Portuguese scientists have developed an optical method to detect cancer
Strive for an accurate diagnosis
The technology should immediately alert pathologists to suspicious areas by identifying characteristics of malignant cells captured by previous training on large data sets of biopsies. This assesses the size of the tumor and how aggressive it is.
The project is led by Oxford urologic histopathologist Clare Verrill. He said: “One of our main goals in healthcare is to detect cancers accurately and at an early stage so that treatment can proceed quickly and ultimately improve patient outcomes. If we can use this diagnostic technology to achieve this, it will be great news for patients.
Impact on workflow
“That’s why this evaluation – the first of its kind – is an important step. Not only will we see how well this software works in a busy clinical environment and whether it improves diagnostic accuracy and efficiency, we’ll also evaluate the clinician and patient experience and see the impact on workflow. For example, OUH Pathology Specialists use AI applications to read prostate biopsy slides as part of their routine work.
He added: “In 2020, OUH’s histopathology laboratory will be the first in the UK to achieve the milestone of scanning 100 per cent of its surgical histology workload. Our experience in digital pathology creates an ideal environment to test AI technologies like the Paige Prostate Suite in a real clinical environment.
